Year: 2022

news_6

Japan Gift Card and Incentive Card Market Report 2022: Market is Expected to Grow by 10.7% to Reach $20,188.0 Million in 2022 – Forecast to 2026 – ResearchAndMarkets.com

Alex February 15, 2022

DUBLIN--(BUSINESS WIRE)--The "Japan Gift Card and Incentive Card Market Intelligence and Future Growth Dynamics (Databook) - Q1 2022 Update" report...

Read MoreRead more about Japan Gift Card and Incentive Card Market Report 2022: Market is Expected to Grow by 10.7% to Reach $20,188.0 Million in 2022 – Forecast to 2026 – ResearchAndMarkets.com
news_6

Japan Gift Card and Incentive Card Market Report 2022: Market is Expected to Grow by 10.7% to Reach $20,188.0 Million in 2022 – Forecast to 2026 – ResearchAndMarkets.com

Alex February 15, 2022

DUBLIN--(BUSINESS WIRE)--The "Japan Gift Card and Incentive Card Market Intelligence and Future Growth Dynamics (Databook) - Q1 2022 Update" report...

Read MoreRead more about Japan Gift Card and Incentive Card Market Report 2022: Market is Expected to Grow by 10.7% to Reach $20,188.0 Million in 2022 – Forecast to 2026 – ResearchAndMarkets.com
news_6

Japan Gift Card and Incentive Card Market Report 2022: Market is Expected to Grow by 10.7% to Reach $20,188.0 Million in 2022 – Forecast to 2026 – ResearchAndMarkets.com

Alex February 15, 2022

DUBLIN--(BUSINESS WIRE)--The "Japan Gift Card and Incentive Card Market Intelligence and Future Growth Dynamics (Databook) - Q1 2022 Update" report...

Read MoreRead more about Japan Gift Card and Incentive Card Market Report 2022: Market is Expected to Grow by 10.7% to Reach $20,188.0 Million in 2022 – Forecast to 2026 – ResearchAndMarkets.com
news_6

ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody

Alex February 15, 2022

BETHESDA, Md. & PANGYO, South Korea--(BUSINESS WIRE)--ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory...

Read MoreRead more about ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody
news_6

ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody

Alex February 15, 2022

BETHESDA, Md. & PANGYO, South Korea--(BUSINESS WIRE)--ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory...

Read MoreRead more about ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody
news_6

ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody

Alex February 15, 2022

BETHESDA, Md. & PANGYO, South Korea--(BUSINESS WIRE)--ValenzaBio, Inc., a biopharmaceutical company developing monoclonal antibody (mAb) therapeutics for autoimmune and inflammatory...

Read MoreRead more about ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody
news_6

JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2022 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders

Alex February 15, 2022

- Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology - HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals...

Read MoreRead more about JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2022 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders
news_6

JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2022 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders

Alex February 15, 2022

- Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology - HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals...

Read MoreRead more about JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2022 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders
news_6

JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2022 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders

Alex February 15, 2022

- Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology - HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals...

Read MoreRead more about JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2022 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders
news_6

Asia Pacific Buy Now Pay Later Markets and Investment Opportunities Report 2022: BNPL Payments are Expected to Grow by 61.5% to Reach US$133,696.8 Million in 2022 – Forecast to 2028 – ResearchAndMarkets.com

Alex February 15, 2022

DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Buy Now Pay Later Business and Investment Opportunities - 75+ KPIs on Buy Now Pay Later...

Read MoreRead more about Asia Pacific Buy Now Pay Later Markets and Investment Opportunities Report 2022: BNPL Payments are Expected to Grow by 61.5% to Reach US$133,696.8 Million in 2022 – Forecast to 2028 – ResearchAndMarkets.com
news_6

Asia Pacific Buy Now Pay Later Markets and Investment Opportunities Report 2022: BNPL Payments are Expected to Grow by 61.5% to Reach US$133,696.8 Million in 2022 – Forecast to 2028 – ResearchAndMarkets.com

Alex February 15, 2022

DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Buy Now Pay Later Business and Investment Opportunities - 75+ KPIs on Buy Now Pay Later...

Read MoreRead more about Asia Pacific Buy Now Pay Later Markets and Investment Opportunities Report 2022: BNPL Payments are Expected to Grow by 61.5% to Reach US$133,696.8 Million in 2022 – Forecast to 2028 – ResearchAndMarkets.com

You may have missed

court-martial-proceedings-begin-against-two-navy-officers-over-ins-brahmaputra-capsize-1793809103

Court-martial proceedings begin against two Navy officers over INS Brahmaputra capsize

Arjun Nair November 4, 2026
cabinet-grants-agniveers-two-more-years-and-a-wider-route-into-regular-forces-1793807285

Cabinet grants Agniveers two more years and a wider route into regular forces

Vivek Raj November 4, 2026
zverevs-no-1-debut-ends-in-straight-sets-what-the-musetti-loss-actually-says-1793805509

Zverev’s No. 1 debut ends in straight sets: what the Musetti loss actually says

Vivek Raj November 4, 2026
ssc-cgl-answer-key-2026-gives-candidates-a-response-sheet-to-audit-not-a-result-to-trust-1793803704

SSC CGL answer key 2026 gives candidates a response sheet to audit, not a result to trust

Vivek Raj November 4, 2026
uae-and-oman-battle-for-standings-edge-in-icc-world-cup-league-2-push-1793801889

UAE and Oman Battle for Standings Edge in ICC World Cup League 2 Push

Vivek Raj November 4, 2026